Biomarkers and Parkinson's disease

被引：115

作者：

Michell, AW ^{[1
]}

Lewis, SJG ^{[1
]}

Foltynie, T ^{[1
]}

Barker, RA ^{[1
]}

机构：

[1] Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England

来源：

BRAIN | 2004年 / 127卷

基金：

英国医学研究理事会;

关键词：

biomarkers; Parkinson's disease; diagnosis;

D O I：

10.1093/brain/awh198

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Biomarkers are characteristics that can be measured as an indicator of a normal biological process, and they have special relevance in Parkinson's disease. Parkinson's disease is a chronic neurodegenerative disorder that is difficult to study, given the site of pathology and because the resultant clinical phenotype fluctuates over time. We currently have no definitive diagnostic test, and thus for the clinician there is hope that biomarkers will help diagnose symptomatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of new treatments, such as neuroprotective therapies, and help stratify this heterogeneous disease. No biomarker is likely to fulfil all these functions, so we need to know how each has been validated in order to understand their uses and limitations, and be aware of potential pitfalls. In this review we discuss the current potential biomarkers for Parkinson's disease, highlight the problems with their use, and conclude with a discussion of future alternatives.

引用

页码：1693 / 1705

页数：13

共 157 条

[11] Echogenicity of the substantia nigra in Parkinsons disease and its relation to clinical findings [J].

Berg, D ;

Siefker, C ;

Becker, G .

JOURNAL OF NEUROLOGY, 2001, 248 (08) :684-689

[12] Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy [J].

Berg, D ;

Jabs, B ;

Merschdorf, U ;

Beckmann, H ;

Becker, G .

BIOLOGICAL PSYCHIATRY, 2001, 50 (06) :463-467

[13] Relationship of substantia nigra echogenicity and motor function in elderly subjects [J].

Berg, D ;

Siefker, C ;

Ruprecht-Dörfler, P ;

Becker, G .

NEUROLOGY, 2001, 56 (01) :13-17

[14] Vulnerability of the nigrostriatal system as detected by transcranial ultrasound [J].

Berg, D ;

Becker, G ;

Zeiler, B ;

Tucha, O ;

Hofmann, E ;

Preier, M ;

Benz, P ;

Jost, W ;

Reiners, K ;

Lange, KW .

NEUROLOGY, 1999, 53 (05) :1026-1031

[15] MITOCHONDRIAL RESPIRATORY-FAILURE IN SKELETAL-MUSCLE FROM PATIENTS WITH PARKINSONS-DISEASE AND MULTIPLE SYSTEM ATROPHY [J].

BLIN, O ;

DESNUELLE, C ;

RASCOL, O ;

BORG, M ;

SAINTPAUL, HP ;

AZULAY, JP ;

BILLE, F ;

FIGARELLA, D ;

COULOM, F ;

PELLISSIER, JF ;

MONTASTRUC, JL ;

CHATEL, M ;

SERRATRICE, G .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 125 (01) :95-101

[16]

Bodis-Wollner I, 1987, Adv Neurol, V45, P323

[17] PLATELET MONOAMINE OXIDASE-B ACTIVITY IN PARKINSONIAN-PATIENTS [J].

BONUCCELLI, U ;

PICCINI, P ;

DELDOTTO, P ;

PACIFICI, GM ;

CORSINI, GU ;

MURATORIO, A .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (10) :854-855

[18] Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects [J].

Borghi, R ;

Marchese, R ;

Negro, A ;

Marinelli, L ;

Forloni, G ;

Zaccheo, D ;

Abbruzzese, G ;

Tabaton, M .

NEUROSCIENCE LETTERS, 2000, 287 (01) :65-67

[19]

Braak H, 2002, J NEUROL S3, V249, P1, DOI DOI 10.1007/S00415-002-1301-4

[20] The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes [J].

Braune, S .

CLINICAL AUTONOMIC RESEARCH, 2001, 11 (06) :351-355

← 1 2 3 4 5 6 7 8 9 10 →